Cardiac Disease

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Cardiac Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Daiichi Sankyo.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Daiichi Sankyo

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed4 · 44%

Recruiting3 · 33%

Unknown status1 · 11%

Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Dynamic Cardio-, Cerebro-vascular and Cortical Interaction in Healthy Adult Subjects

Recruiting·IIRCCS Policlinico S. Donato·Preclinical·NCT06785181·50 enrolled

Predicting Cerebrovascular Adverse Events Post Cardiac Surgery With Cardiopulmonary Bypass by Means of Cerebral AutoreguLation Indices

Recruiting·IIRCCS Policlinico S. Donato·Preclinical·NCT05786274·104 enrolled

BoStOn SCientific Rhythm MAnagemenT REgiStry

Recruiting·BBoston Scientific Corporation·N/A·NCT04823663·12,500 enrolled

A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Active, not recruiting·TTrust Bio-sonics, Inc.·Phase 3·NCT06815627·150 enrolled

Reduction of Smoking in Cardiac Disease Patients

Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00469885·152 enrolled

Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease

Completed·JJKastrup·Phase 2·NCT02673164·133 enrolled

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT03395639·168 enrolled

Development of Guidance Algorithms for Acquisition of Echocardiographic Reference Views

Completed·UUniversity Hospital, Bordeaux·Preclinical·NCT05490303·90 enrolled

Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

Unknown status·—·N/A·NCT06297681·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)